Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJHM1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

```
 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  MAY 01  New CAS web site launched
 NEWS  3  MAY 08  CA/CAplus Indian patent publication number format defined
 NEWS  4  MAY 14  RDISCLOSURE on STN Easy enhanced with new search and display
                  fields
 NEWS  5  MAY 21  BIOSIS reloaded and enhanced with archival data
 NEWS  6  MAY 21  TOXCENTER enhanced with BIOSIS reload
 NEWS  7  MAY 21  CA/CAplus enhanced with additional kind codes for German
                  patents
 NEWS  8  MAY 22  CA/CAplus enhanced with IPC reclassification in Japanese
                  patents
 NEWS  9  JUN 27  CA/CAplus enhanced with pre-1967 CAS Registry Numbers
 NEWS 10  JUN 29  STN Viewer now available
 NEWS 11  JUN 29  STN Express, Version 8.2, now available
 NEWS 12  JUL 02  LEMBASE coverage updated
 NEWS 13  JUL 02  LMEDLINE coverage updated
 NEWS 14  JUL 02  SCISEARCH enhanced with complete author names
 NEWS 15  JUL 02  CHEMCATS accession numbers revised
 NEWS 16  JUL 02  CA/CAplus enhanced with utility model patents from China
 NEWS 17  JUL 16  CAplus enhanced with French and German abstracts
 NEWS 18  JUL 18  CA/CAplus patent coverage enhanced
 NEWS 19  JUL 26  USPATFULL/USPAT2 enhanced with IPC reclassification
 NEWS 20  JUL 30  USGENE now available on STN
 NEWS 21  AUG 06  CAS REGISTRY enhanced with new experimental property tags
 NEWS 22  AUG 06  BEILSTEIN updated with new compounds
 NEWS 23  AUG 06  FSTA enhanced with new thesaurus edition
 NEWS 24  AUG 13  CA/CAplus enhanced with additional kind codes for granted
                  patents
 NEWS 25  AUG 20  CA/CAplus enhanced with CAS indexing in pre-1907 records
 NEWS 26  AUG 27  Full-text patent databases enhanced with predefined
                  patent family display formats from INPADOCDB
 NEWS 27  AUG 27  USPATOLD now available on STN
 NEWS 28  AUG 28  CAS REGISTRY enhanced with additional experimental
                  spectral property data

 NEWS EXPRESS  05 SEPTEMBER 2007:  CURRENT WINDOWS VERSION IS V8.2,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 05 SEPTEMBER 2007.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
```

Enter NEWS followed by the item number or name to see news on that specific topic.

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:31:57 ON 06 SEP 2007

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 17:32:07 ON 06 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 SEP 2007 HIGHEST RN 946114-43-8
DICTIONARY FILE UPDATES: 5 SEP 2007 HIGHEST RN 946114-43-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10 series\10537187\10537187a.str



chain nodes :
6 7 14 15 16
ring nodes :
1 2 3 4 5 8 9 10 11 12 13 17 18 19 20 21
chain bonds :
1-6 2-7 7-8 11-14 14-15 14-16
ring bonds :
1-2 1-5 2-3 3-4 3-17 3-21 4-5 8-9 8-13 9-10 10-11 11-12 12-13 17-18 18-19 19-20 20-21
exact/norm bonds :
1-2 1-5 1-6 2-3 2-7 3-4 3-17 3-21 4-5 14-15 14-16 17-18 18-19 19-20 20-21

```
exact bonds :
7-8  11-14
normalized bonds :
8-9  8-13  9-10  10-11  11-12  12-13


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:CLASS  7:CLASS  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:CLASS  15:CLASS  16:CLASS  17:Atom  18:Atom  19:Atom
20:Atom  21:Atom



L1      STRUCTURE UPLOADED

=> s l1\
L2         9853 L1\
                ('L1')

=> s l1
SAMPLE SEARCH INITIATED 17:32:24 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       50 TO ITERATE

100.0% PROCESSED       50 ITERATIONS                                 5 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          576 TO     1424
PROJECTED ANSWERS:               5 TO      234

L3            5 SEA SSS SAM L1

=> d scan
```

L3 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, 4-[[trans-3-(2,4-dichlorophenyl)-8-(1,1-dimethylethyl)-2-oxo-1,3-diazaspiro[4.5]dec-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI)
MF C27 H31 C12 N7 O2

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

```
=> s l1 full
FULL SEARCH INITIATED 17:32:45 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      1003 TO ITERATE

100.0% PROCESSED     1003 ITERATIONS                                  109 ANSWERS
SEARCH TIME: 00.00.01

L4           109 SEA SSS FUL L1

=> d scan
```

L4 109 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, 4-[[trans-8-(1,1-dimethylethyl)-3-[(3-fluorophenyl)methyl]-2-oxo-1,3-diazaspiro[4.5]dec-1-yl]methyl]-N-1H-tetrazol-5-yl- (9CI)
MF C28 H34 F N7 O2

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

```
=> file caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                       177.05     177.26

FILE 'CAPLUS' ENTERED AT 17:32:57 ON 06 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 6 Sep 2007  VOL 147 ISS 11
FILE LAST UPDATED: 5 Sep 2007  (20070905/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l4
L5            2 L4

=> d l5 1-2 ibib abs
```

L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:980867 CAPLUS
DOCUMENT NUMBER: 143:359435
TITLE: Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists
AUTHOR(S): Shen, Dong-Ming; Zhang, Fengqi; Brady, Edward J.; Candelore, Mari Rios; Dallas-Yang, Qing; Ding, Victor D.-H.; Dragovic, Jasminka; Feeney, William P.; Jiang, Guoquiang; McCann, Peggy E.; Mock, Steve; Qureshi, Sajjad A.; Saperstein, Richard; Shen, Xiaolan; Tamvakopoulos, Constantin; Tong, Xinchun; Tota, Laurie M.; Wright, Michael J.; Yang, Xiaodong; Zheng, Song; Chapman, Kevin T.; Zhang, Bei B.; Tata, James R.; Parmee, Emma R.
CORPORATE SOURCE: Department of Basic Chemistry, Merck Research Laboratories, Rahway, NJ, 07065, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(20), 4564-4569
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 143:359435
GI



I

AB A novel class of spiro-ureas has been discovered as potent human glucagon receptor antagonists in both binding and functional assays. Preliminary studies have revealed that compound (I) is an orally active human glucagon receptor antagonist in a transgenic murine pharmacodynamic model at 10 and 30 mpk. Compound I is orally bioavailable in several preclin. species and shows selectivity toward cardiac ion channels and other family B receptors, such as hGIP1 and hGLP.
REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:490706 CAPLUS
DOCUMENT NUMBER: 141:54338
TITLE: Preparation of spirocyclic ureas as glucagon receptor antagonists for the treatment of type 2 diabetes mellitus
INVENTOR(S): Parmee, Emma R.; Zhang, Fengqi; Shen, Dong-Ming; Stelmach, John
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004050039	A2	20040617	WO 2003-US38590		20031126
WO 2004050039	A3	20040729			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2508581	A1	20040617	CA 2003-2508581		20031126
AU 2003298889	A1	20040623	AU 2003-298889		20031126
EP 1569915	A2	20050907	EP 2003-796648		20031126
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2006509015	T	20060316	JP 2004-557589		20031126
US 2006116366	A1	20060601	US 2005-537187		20050602
PRIORITY APPLN. INFO.:			US 2002-430799P	P	20021204
			WO 2003-US38590	W	20031126

OTHER SOURCE(S): MARPAT 141:54338
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I [X = CH2 and C(O); R1 = (substituted)alkyl, (substituted)(hetero)aryl; R2 = H, or alkyl; R3 = H, or F; R4 = H, F, or OH; or R3, R4 = oxo; R5 = H, CO2R6, alkyl optionally substituted with OH, O-alkyl, CO2R6, halo; R6 = H, (substituted)alkyl; Y = (substituted)4-8 membered spirocarbocyclic ring or a spiroheterocyclic ring containing up to 3 heteroatoms, selected from O, S, N; p, q = 0 or 1 with proviso that the sum of p and q is 0 or 1] were prepared as glucagon receptor antagonists for the treatment of type 2 diabetes mellitus. For example, compound II was prepared in a multi-step synthesis starting from 4-tert-butylcyclohexanone.

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

```
=> file registry
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                          ENTRY    SESSION
FULL ESTIMATED COST                                        7.07     184.33

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                          ENTRY    SESSION
CA SUBSCRIBER PRICE                                       -1.56      -1.56

FILE 'REGISTRY' ENTERED AT 17:34:27 ON 06 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     5 SEP 2007  HIGHEST RN 946114-43-8
DICTIONARY FILE UPDATES:    5 SEP 2007  HIGHEST RN 946114-43-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10 series\10537187\10537187b.str
```



```
chain nodes :
6  7  14  15  16
ring nodes :
1  2  3  4  5  8  9  10  11  12  13  17  18  19  20
chain bonds :
1-6  2-7  7-8  11-14  14-15  14-16
ring bonds :
1-2  1-5  2-3  3-4  3-17  3-20  4-5  8-9  8-13  9-10  10-11  11-12  12-13  17-18
18-19  19-20
```

```
exact/norm bonds :
1-2  1-5  1-6  2-3  2-7  3-4  3-17  3-20  4-5  14-15  14-16  17-18  18-19  19-20
exact bonds :
7-8  11-14
normalized bonds :
8-9  8-13  9-10  10-11  11-12  12-13


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:CLASS  7:CLASS  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:CLASS  15:CLASS  16:CLASS  17:Atom  18:Atom  19:Atom
20:Atom



L6      STRUCTURE UPLOADED

=> s l6
SAMPLE SEARCH INITIATED 17:34:42 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       50 TO ITERATE

100.0% PROCESSED       50 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          576 TO     1424
PROJECTED ANSWERS:               0 TO        0

L7             0 SEA SSS SAM L6

=> s l6 full
FULL SEARCH INITIATED 17:34:46 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     1003 TO ITERATE

100.0% PROCESSED     1003 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

L8             0 SEA SSS FUL L6

=>
Uploading C:\Program Files\Stnexp\Queries\10 series\10537187\10537187c.str
```





```
chain nodes :
6  7  14  15  16  17  18
ring nodes :
1  2  3  4  5  8  9  10  11  12  13
```

```
chain bonds :
1-6  2-7  3-17  3-18  7-8  11-14  14-15  14-16
ring bonds :
1-2  1-5  2-3  3-4  4-5  8-9  8-13  9-10  10-11  11-12  12-13
exact/norm bonds :
1-2  1-5  1-6  2-3  2-7  3-4  3-17  3-18  4-5  14-15  14-16
exact bonds :
7-8  11-14
normalized bonds :
8-9  8-13  9-10  10-11  11-12  12-13


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:CLASS  7:CLASS  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:CLASS  15:CLASS  16:CLASS  17:Atom  18:Atom



L9      STRUCTURE UPLOADED

=> d l9
L9 HAS NO ANSWERS
L9              STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l9
SAMPLE SEARCH INITIATED 17:36:16 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      385 TO ITERATE

100.0% PROCESSED      385 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         6523 TO     8877
PROJECTED ANSWERS:               0 TO        0

L10           0 SEA SSS SAM L9

=> s l9 full
```

FULL SEARCH INITIATED 17:36:20 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 7936 TO ITERATE

100.0% PROCESSED 7936 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L11 0 SEA SSS FUL L9

=>
Uploading C:\Program Files\Stnexp\Queries\10 series\10537187\10537187d.str





chain nodes :
4 5 12 13 14
ring nodes :
1 2 3 6 7 8 9 10 11 15 16 17 18
chain bonds :
1-4 2-5 5-6 9-12 12-13 12-14
ring bonds :
1-2 1-3 2-18 3-15 6-7 6-11 7-8 8-9 9-10 10-11 15-16 16-17 17-18
exact/norm bonds :
1-2 1-3 1-4 2-5 2-18 3-15 5-6 9-12 12-13 12-14 15-16 16-17 17-18

normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11

G1:CH2,C

Match level :
1:Atom 2:Atom 3:Atom 4:CLASS 5:CLASS 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:Atom 18:Atom

L12 STRUCTURE UPLOADED

=> d l12
L12 HAS NO ANSWERS
L12 STR



G1 CH2,C

Structure attributes must be viewed using STN Express query preparation.

=> s l12
SAMPLE SEARCH INITIATED 17:40:03 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 908 TO ITERATE

100.0% PROCESSED 908 ITERATIONS 42 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 16353 TO 19967
PROJECTED ANSWERS: 452 TO 1228

L13 42 SEA SSS SAM L12

=> d scan

L13 42 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide,
4-[[3-[[1-[2-(dimethylamino)ethyl]-1H-benzimidazol-2-yl]methyl]-
2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]methyl]-N-(4-pyridinylmethyl)-
(9CI)
MF C33 H33 N7 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

```
=> s l12 full
FULL SEARCH INITIATED 17:40:42 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    18212 TO ITERATE

100.0% PROCESSED    18212 ITERATIONS                          857 ANSWERS
SEARCH TIME: 00.00.01

L14          857 SEA SSS FUL L12

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                             519.90     704.23

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                               0.00      -1.56

FILE 'CAPLUS' ENTERED AT 17:40:46 ON 06 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 6 Sep 2007  VOL 147 ISS 11
FILE LAST UPDATED: 5 Sep 2007  (20070905/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l14
L15          42 L14

=> d l15 1-10 ibib abs hitstr
```

L15 ANSWER 1 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:629269 CAPLUS
DOCUMENT NUMBER: 147:226216
TITLE: Exploring Experimental Sources of Multiple Protein Conformations in Structure-Based Drug Design
AUTHOR(S): Damm, Kelly L.; Carlson, Heather A.
CORPORATE SOURCE: Department of Medicinal Chemistry, University of Michigan, Ann Arbor, MI, 48109-1065, USA
SOURCE: Journal of the American Chemical Society (2007), 129(26), 8225-8235
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Receptor flexibility must be incorporated into structure-based drug design to portray a more accurate representation of a protein in solution Our approach is to generate pharmacophore models based on multiple conformations of a protein and is very similar to solvent mapping of hot spots. Previously, we had success using computer-generated conformations of apo human immunodeficiency virus-1 protease (HIV-1p). Here, we examine the use of an NMR ensemble vs. a collection of crystal structures, and we compare back to our previous study based on computer-generated conformations. To our knowledge, this is the first direct comparison of an NMR ensemble and a collection of crystal structures to incorporate protein flexibility in structure-based drug design. To provide an accurate comparison between the exptl. sources, we used bound structures for our multiple protein structure (MPS) pharmacophore models. The models from an NMR ensemble and a collection of crystal structures were both able to discriminate known HIV-1p inhibitors from decoy mols. and displayed superior performance over models created from single conformations of the protein. Although the active-site conformations were already predefined by bound ligands, the use of MPS allows us to overcome the cross-docking problem and generate a model that does not simply reproduce the chemical characteristics of a specific ligand class. We show that there is more structural variation between 28 structures in an NMR ensemble than 90 crystal structures bound to a variety of ligands. MPS models from both sources performed well, but the model determined using the NMR ensemble appeared to be the most general yet accurate representation of the active site. This work encourages the use of NMR models in structure-based design.

IT 945386-48-1 945386-49-2 945386-50-5
RL: PAC (Pharmacological activity); BIOL (Biological study)
(exploring exptl. sources of multiple protein conformations in structure-based drug design)

RN 945386-48-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

L15 ANSWER 1 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 76 THERE ARE 76 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 1 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 945386-49-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 945386-50-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

L15 ANSWER 2 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:512058 CAPLUS
DOCUMENT NUMBER: 146:481830
TITLE: Substituted benzamide and 11β-hydroxysteroid dehydrogenase type 1 and their preparation and pharmaceutical use
INVENTOR(S): Andersen, Henrik Sune; Joergensen, Anker Steen; Kilburn, John Paul; Kampen, Gita Camilla Tejlgaard; Ebdrup, Soeren
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 185pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007051810	A2	20070510	WO 2006-EP68015	20061101

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: EP 2005-110228 A 20051101
EP 2006-116808 A 20060707

OTHER SOURCE(S): MARPAT 146:481830
GI



I



II

AB The use of substituted amides of formula I for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compds. as pharmaceutical compns., are described. Also a class of substituted amides of formula I, their use in therapy, pharmaceutical compns. comprising the compds., as well as their use in the manufacture of medicaments are described. Compound of formula I wherein R1 is H, acyl, (amino)sulfonyl, (amino)sulfinyl, etc.; R2 is H, C1-6 alkyl, and C3-6 cycloalkyl; R1R2 taken together with N to form (un)substituted (un)saturated 3- to 12-membered (mono/bi)heterocyclic ring; A is (un)substituted (un)saturated 5- to 12-membered (bi/tri)heterocyclic; R5 is H, C1-6 alkyl, C3-6 cycloalkyl, halo, OH, and CN; R6 and R7 is H, C1-6 alkyl, F, trihalomethyl, and trihalomethoxy; R6R7 taken together to give (un)substituted (un)saturated 3- to 8-membered (hetero)monocyclic; and their prodrugs, pharmaceutically acceptable acid and base salts, optical isomers, mixts. of optical isomers, racemic mixts., tautomeric forms thereof, are claimed. The compds. are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable. Example compound II was prepared by amidation ot 4-(tert-butoxycarbonylaminomethyl)benzoic acid with 1,3,3-trimethyl-6-azabicyclo[3.2.1]octane hydrochloride; the resulting [4-(1,3,3-trimethyl-6-azabicyclo[3.2.1]octane-6-carbonyl)benzyl]carbamic acid tert-Bu ester underwent methylation with Me iodide to give methyl-[4-(1,3,3-trimethyl-6-azabicyclo[3.2.1]octane-6-carbonyl)benzyl]carbamic acid tert-Bu ester, which underwent hydrolysis to give (4-methylaminomethylphenyl)-(1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl)methanone, which underwent acetylation with acetyl chloride to give compound II. All the invention compds. were evaluated for their 11βHSD1 inhibitory activity. From the assay, it was determined that compound II exhibited an IC50 value of 19 nM.

IT 936019-73-7P 936019-76-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzamide derivs. as 11β-hydroxysteroid dehydrogenase type 1 inhibitors useful in the treatment of diseases)

RN 936019-73-7 CAPLUS
CN Benzamide, 4-[[3-(4-fluorophenyl)-2-oxo-1-imidazolidinyl]methyl]-N-tricyclo[3.3.1.13,7]dec-2-yl- (CA INDEX NAME)



RN 936019-76-0 CAPLUS
CN Benzamide, 4-[(2-oxo-3-phenyl-1-imidazolidinyl)methyl]-N-tricyclo[3.3.1.13,7]dec-2-yl- (CA INDEX NAME)



ACCESSION NUMBER: 2007:382169 CAPLUS
DOCUMENT NUMBER: 147:109049
TITLE: Respiratory syncytial virus fusion inhibitors. Part 4: Optimization for oral bioavailability. [Erratum to document cited in CA146:287664]
AUTHOR(S): Yu, Kuo-Long; Sin, Ny; Civiello, Rita L.; Wang, X. Alan; Combrink, Keith D.; Gulgeze, H. Belgin; Venables, Brian L.; Wright, J. J. Kim; Dalterio, Richard A.; Zadjura, Lisa; Marino, Anthony; Dando, Sandra; D'Arienzo, Celia; Kadow, Kathleen F.; Cianci, Christopher W.; Li, Zhufang; Clarke, Junius; Genovesi, Eugene V.; Medina, Ivette; Lamb, Lucinda; Colonno, Richard J.; Yang, Zheng; Krystal, Mark; Meanwell, Nicholas A.
CORPORATE SOURCE: Department of Chemistry, The Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT, 06492, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(8), 2385
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB On page 899, the protecting groups on the chemical structures of compds. 9 and 10 in Scheme 1 are depicted on the wrong nitrogen atoms of the urea element. The correct chemical structures are given.

IT 880550-49-2P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(benzimidazole-based inhibitors of respiratory syncytial virus fusion (Erratum))

RN 880550-49-2 CAPLUS
CN Benzamide, 4-[[3-[[1-[2-(dimethylamino)ethyl]-1H-benzimidazol-2-yl]methyl]-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]methyl]-N,N-dimethyl- (CA INDEX NAME)



L15 ANSWER 4 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:129869 CAPLUS
DOCUMENT NUMBER: 146:287664
TITLE: Respiratory syncytial virus fusion inhibitors. Part 4:
Optimization for oral bioavailability
AUTHOR(S): Yu, Kuo-Long; Sin, Ny; Civiello, Rita L.; Wang, X. Alan; Combrink, Keith D.; Gulgeze, H. Belgin; Venables, Brian L.; Wright, J. J. Kim; Dalterio, Richard A.; Zadjura, Lisa; Marino, Anthony; Dando, Sandra; D'Arienzo, Celia; Kadow, Kathleen F.; Cianci, Christopher W.; Li, Zhufang; Clarke, Junius; Genovesi, Eugene V.; Medina, Ivette; Lamb, Lucinda; Colonno, Richard J.; Yang, Zheng; Krystal, Mark; Meanwell, Nicholas A.
CORPORATE SOURCE: Department of Chemistry, The Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT, 06492, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(4), 895-901
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB A series of benzimidazole-based inhibitors of respiratory syncytial virus (RSV) fusion were optimized for antiviral potency, membrane permeability and metabolic stability in human liver microsomes. 1-Cyclopropyl-1,3-dihydro-3-[[1-(4-hydroxybutyl)-1H-benzimidazol-2-yl]methyl]-2H-imidazo[4,5-c]pyridin-2-one (I, BMS-433771) was identified as a potent RSV inhibitor demonstrating good bioavailability in the mouse, rat, dog and cynomolgus monkey that demonstrated antiviral activity in the BALB/c and cotton rat models of infection following oral administration.
IT 880550-49-2P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(benzimidazole-based inhibitors of respiratory syncytial virus fusion)
RN 880550-49-2 CAPLUS
CN Benzamide, 4-[[3-[[1-[2-(dimethylamino)ethyl]-1H-benzimidazol-2-yl]methyl]-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]methyl]-N,N-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 5 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:15632 CAPLUS
DOCUMENT NUMBER: 146:267697
TITLE: Cloning and expression of canine glucagon receptor and its use to evaluate glucagon receptor antagonists in vitro and in vivo
AUTHOR(S): Yang, Xiaodong; Yates, Marla L.; Candelore, Mari R.; Feeney, William; Hora, Don; Kim, Ron M.; Parmee, Emma R.; Berger, Joel P.; Zhang, Bei B.; Qureshi, Sajjad A.
CORPORATE SOURCE: Department of Metabolic Disorder-Molecular Endocrinology, Merck Research Laboratories, Rahway, NJ, 07065, USA
SOURCE: European Journal of Pharmacology (2007), 555(1), 8-16
CODEN: EJPHAZ; ISSN: 0014-2999
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Glucose homeostasis is maintained by the combined actions of insulin and glucagon. Hyperglucagonemia and/or elevation of glucagon/insulin ratio have been reported in diabetic patients and in animal models of diabetes. Therefore, antagonizing glucagon receptor function has long been considered a useful approach to lower hyperglycemia. Dogs serve as an excellent model for studying glycemic control and various aspects of glucagon biol. in vivo; however, the amino acid sequence of the dog glucagon receptor has not been reported. To better understand the pharmacol. of the dog glucagon receptor and to characterize glucagon receptor antagonists, we cloned a cDNA corresponding to the glucagon receptor from dog liver RNA. The dog glucagon receptor shares a significant (> 75%) homol. at both nucleotide and amino acid levels with the glucagon receptor from human, monkey, mouse, and rat. The protein is highly conserved among all species in areas corresponding to the 7 trans-membrane domains. However, it shows significant divergence at the carboxy terminus such that the receptor from dog has the longest cytoplasmic tail among all species examined. When expressed in chinese hamster ovary cells, the dog glucagon receptor bound [125I]Glucagon with a Kd of 477 ± 106 pM. Glucagon stimulated the rise of intracellular cAMP levels in these cells with an EC50 of 9.6 ± 1.7 nM and such effects could be blocked by known peptidyl and non-peptidyl small mol. antagonists. In addition we show that a small mol. glucagon receptor antagonist with significant activity in cell based assays also blocked the ability of glucagon to induce elevation in blood glucose in beagle dogs. These data demonstrate that the cloned cDNA encodes a functional dog glucagon receptor. The availability of the dog cDNA will facilitate the understanding of glucagon pharmacol. and aid in the characterization of novel glucagon antagonists that may serve as anti-hyperglycemic treatment for type 2 diabetes mellitus.
IT 706812-04-6
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(glucagon receptor antagonist; cloning, protein and cDNA sequences and expression of canine glucagon receptor and its use to evaluate glucagon receptor antagonists in vitro and in vivo)
RN 706812-04-6 CAPLUS
CN Benzamide, 4-[[9-(1,1-dimethylethyl)-2-oxo-3-[4-(trifluoromethoxy)phenyl]-1,3-diazaspiro[5.5]undec-1-yl]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 6 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1204441 CAPLUS
DOCUMENT NUMBER: 145:505484
TITLE: Preparation of benzo[1,2,4]thiadiazines as histone deacetylase inhibitors for treating inflammation, cancer, and other diseases
INVENTOR(S): Bressi, Jerome C.; Brown, Jason W.; Gangloff, Anthony R.; Stafford, Jeffrey A.; Vu, Phong H.
PATENT ASSIGNEE(S): Takeda San Diego, Inc., USA
SOURCE: PCT Int. Appl., 180pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006122319	A2	20061116	WO 2006-US18645	20060510
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006258694	A1	20061116	US 2006-382659	20060510
PRIORITY APPLN. INFO.:			US 2005-679923P	P 20050511

OTHER SOURCE(S): MARPAT 145:505484
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Compds., pharmaceutical compns., kits and methods are provided for use with HDAC that comprise a compound selected from the group consisting of formula I and formula II, wherein n = 0-4; A1 = (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, etc.; L = a linker; X = CH2, CS, SO and SO2; Y = oxo, sulfo and R10; R1 and R2 = H, OH, alkoxy, aryloxy, heteroaryloxy, (C1-10)alkylamino, sulfonamido, etc.; R3 = H, OH, alkoxy, aryloxy, heteroaryloxy, sulfinyl, etc.; R4 = H, halo, nitro, cyano, thio, hydroxy, etc.; R5, R6, R7 and R8 = H, halo, nitro, cyano, thio, OH, alkoxy, etc.; R9 = H, OH, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C1-10)alkylamino, etc.; and R10 = H, OH, alkoxy, aryloxy, heteroaryloxy, etc. Preparation of I and II by 1 of 3 reaction schemes is exemplified. The IC50 values of the compds. of the invention against HDAC2 ranged from <50 nM to >500 nM in vitro. I and II are useful in treating cancer, inflammation, degenerative eye disease, multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, and hyperproliferation skin diseases.

IT 914261-83-9P, N-(2-Aminophenyl)-4-[(3-methyl-2-oxo-3,4-dihydro-2H-quinazolin-1-yl)methyl]benzamide

L15 ANSWER 6 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L15 ANSWER 6 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; prepn. of benzo[1,2,4]thiadiazines as histone deacetylase inhibitors for treating inflammation, cancer, and other diseases)
RN 914261-83-9 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(3,4-dihydro-3-methyl-2-oxo-1(2H)-quinazolinyl)methyl]- (9CI) (CA INDEX NAME)



IT 914261-77-1P, N-(2-Aminophenyl)-4-[(2-oxo-3,4-dihydroquinazolin-1(2H)-yl)methyl]benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzo[1,2,4]thiadiazines as histone deacetylase inhibitors for treating inflammation, cancer, and other diseases)
RN 914261-77-1 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(3,4-dihydro-2-oxo-1(2H)-quinazolinyl)methyl]- (9CI) (CA INDEX NAME)

L15 ANSWER 7 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:608746 CAPLUS
DOCUMENT NUMBER: 145:78748
TITLE: Histone deacetylase inhibitors for use as antitumor, antiarthritic, and anti-Alzheimer drugs
INVENTOR(S): Bressi, Jerom C.; Brown, Jason W.; Gangloff, Anthony R.; Jennings, Andrew J.; Kaldor, Stephen W.; Skene, Robert J.; Stafford, Jeffrey A.; Vu, Phong H.
PATENT ASSIGNEE(S): Takeda San Diego, Inc., USA
SOURCE: PCT Int. Appl., 257 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006066133	A2	20060622	WO 2005-US45779	20051216
WO 2006066133	A3	20060831		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006205941	A1	20060914	US 2005-303455	20051216
EP 1824831	A2	20070829	EP 2005-857114	20051216
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.:			US 2004-636974P	P 20041216
			WO 2005-US45779	W 20051216

OTHER SOURCE(S): MARPAT 145:78748
AB Compds. for use as histone deacetylase inhibitors and their use to treat various diseases, including cancer, inflammation, and arthritis, are disclosed. Thus, a large number of benzimidazol-2-one derivs. are provided.
General procedures for synthesis of these types of compds. are described.

IT 890782-36-2P 890782-52-2P 890782-60-2P
890782-68-0P 890782-84-0P 890782-92-0P
890783-00-3P 890783-24-1P 890783-56-9P
890783-64-9P 890783-72-9P 890783-88-7P
890784-04-0P 890784-12-0P 890784-36-8P
890784-44-8P 890784-52-8P 890784-60-8P
890784-68-6P 890784-75-5P 890784-82-4P
890784-89-1P 890784-96-0P 890785-03-2P
890785-10-1P 890785-17-8P 890785-31-6P
890785-38-3P 890785-45-2P 890785-80-5P
890785-87-2P 890786-03-5P 890786-34-2P
890786-50-2P 890786-66-0P 890786-82-0P
890786-90-0P 890786-98-8P 890787-06-1P
890787-14-1P 890787-22-1P 890787-30-1P
890787-38-9P 890787-46-9P 890787-54-9P

890787-62-9P 890787-70-9P 890787-78-7P
890787-86-7P 890787-94-7P 890788-02-0P
890788-10-0P 890788-18-8P 890788-26-8P
890788-34-8P 890788-42-8P 890788-50-8P
890789-14-7P 890789-30-7P 890789-70-5P
890789-78-3P 890789-86-3P 890789-94-3P
890790-02-0P 890790-10-0P 890790-18-8P
890790-26-8P 890790-34-8P 890790-42-8P
890790-50-8P 890790-72-4P 890790-93-9P
890791-00-1P 890791-07-8P 890791-14-7P
890791-21-6P 890791-28-3P 890791-35-2P
890791-42-1P 890791-82-9P 890791-98-7P
890792-14-0P 890792-30-0P 890792-38-8P
890792-46-8P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(histone deacetylase inhibitors for use as antitumor, antiarthritic, and anti-Alzheimer drugs)

RN 890782-36-2 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890782-52-2 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890782-60-2 CAPLUS
CN Benzamide,
4-[(4-amino-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)methyl]-N-(2-aminophenyl)- (9CI) (CA INDEX NAME)



RN 890782-68-0 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(2-oxo-1-imidazolidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 890783-24-1 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(1,2-dihydro-2-oxo-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890783-56-9 CAPLUS
CN Benzamide,
N-(2-aminophenyl)-4-[(2,3-dihydro-4-nitro-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890783-64-9 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(3-cyclohexyl-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890783-72-9 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)methyl]-3-nitro- (9CI) (CA INDEX NAME)



RN 890782-84-0 CAPLUS
CN Benzamide,
N-(2-aminophenyl)-4-[(2,3-dihydro-7-nitro-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890782-92-0 CAPLUS
CN Benzamide,
4-[(7-amino-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)methyl]-N-(2-aminophenyl)- (9CI) (CA INDEX NAME)



RN 890783-00-3 CAPLUS
CN Benzamide,
N-(2-aminophenyl)-4-[(2,3-dihydro-5-nitro-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890783-88-7 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[[2,3-dihydro-3-(1-methylethyl)-2-oxo-1H-benzimidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 890784-04-0 CAPLUS
CN Benzamide, N-(4-amino[1,1'-biphenyl]-3-yl)-4-[(1,2-dihydro-2-oxo-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890784-12-0 CAPLUS
CN Benzamide, N-(4-amino[1,1'-biphenyl]-3-yl)-4-[(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890784-36-8 CAPLUS
CN Benzamide,
N-(2-aminophenyl)-4-[(5-cyano-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890784-44-8 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(6-cyano-2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890784-52-8 CAPLUS
CN 2-Pyridinecarboxamide,
N-[[3-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-2,3-dihydro-1-methyl-2-oxo-1H-benzimidazol-5-yl]methyl]- (9CI) (CA INDEX NAME)



RN 890784-60-8 CAPLUS
CN 3-Pyridinecarboxamide,
N-[[3-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-2,3-dihydro-1-methyl-2-oxo-1H-benzimidazol-5-yl]methyl]- (9CI) (CA INDEX NAME)



RN 890784-68-6 CAPLUS
CN 4-Pyridinecarboxamide,
N-[[3-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-2,3-dihydro-1-methyl-2-oxo-1H-benzimidazol-5-yl]methyl]- (9CI) (CA INDEX NAME)



RN 890784-75-5 CAPLUS
CN 2-Pyridinecarboxamide,
N-[[1-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-2,3-dihydro-2-oxo-1H-benzimidazol-5-yl]methyl]- (9CI) (CA INDEX NAME)



RN 890784-82-4 CAPLUS
CN 3-Pyridinecarboxamide,
N-[[1-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-2,3-dihydro-2-oxo-1H-benzimidazol-5-yl]methyl]- (9CI) (CA INDEX NAME)



RN 890784-89-1 CAPLUS
CN 4-Pyridinecarboxamide,
N-[[1-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-2,3-dihydro-2-oxo-1H-benzimidazol-5-yl]methyl]- (9CI) (CA INDEX NAME)



RN 890784-96-0 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[[2,3-dihydro-3-[(3R)-1-methyl-3-piperidinyl]-2-oxo-1H-benzimidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 890785-03-2 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[[3-[(3R)-1-ethyl-3-piperidinyl]-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 890785-10-1 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(6-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890785-17-8 CAPLUS
CN Benzamide,
N-(2-aminophenyl)-4-[(6-bromo-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890785-31-6 CAPLUS
CN Benzamide, 4-[(3-acetyl-6-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)methyl]-N-(2-aminophenyl)- (9CI) (CA INDEX NAME)



RN 890785-38-3 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[[6-fluoro-2,3-dihydro-2-oxo-3-(1-oxopropyl)-1H-benzimidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 890785-45-2 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(5-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890785-80-5 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(4-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890785-87-2 CAPLUS
CN Benzamide,
N-(2-aminophenyl)-4-[(5-bromo-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890786-03-5 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(6-cyano-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890786-34-2 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(2,3-dihydro-6-methyl-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890786-50-2 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(2,3-dihydro-5-methoxy-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890786-66-0 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(5-ethoxy-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890786-82-0 CAPLUS

CN Benzamide, N-(2-aminophenyl)-4-[[5-(3-furanyl)-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 890787-30-1 CAPLUS
CN Benzamide, 4-[[5-(3-amino-3-oxo-1-propenyl)-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]methyl]-N-(2-aminophenyl)- (9CI) (CA INDEX NAME)



RN 890787-38-9 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[[2,3-dihydro-3-(2-hydroxyethyl)-2-oxo-1H-benzimidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 890787-46-9 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 890787-54-9 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[[1,2-dihydro-1-(2-methoxyethyl)-2-oxo-3H-imidazo[4,5-b]pyridin-3-yl]methyl]- (9CI) (CA INDEX NAME)

CN Benzamide, N-(2-aminophenyl)-4-[[2,3-dihydro-2-oxo-5-(3-thienyl)-1H-benzimidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 890786-90-0 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[[2,3-dihydro-2-oxo-5-(3-pyridinyl)-1H-benzimidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 890786-98-8 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[[2,3-dihydro-2-oxo-5-(1H-pyrrol-3-yl)-1H-benzimidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 890787-06-1 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[[2,3-dihydro-2-oxo-5-(4-pyridinyl)-1H-benzimidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 890787-14-1 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[[2,3-dihydro-2-oxo-5-(2-thienyl)-1H-benzimidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 890787-22-1 CAPLUS



RN 890787-62-9 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[[1,2-dihydro-1-(2-hydroxyethyl)-2-oxo-3H-imidazo[4,5-b]pyridin-3-yl]methyl]- (9CI) (CA INDEX NAME)



RN 890787-70-9 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[[2,3-dihydro-3-(2-hydroxypropyl)-2-oxo-1H-benzimidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 890787-78-7 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[[6-fluoro-2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 890787-86-7 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[[6-fluoro-2,3-dihydro-3-(2-hydroxyethyl)-2-oxo-1H-benzimidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 890787-94-7 CAPLUS
CN Benzamide,
N-(2-aminophenyl)-4-[[1,2-dihydro-1-(2-hydroxypropyl)-2-oxo-3H-imidazo[4,5-b]pyridin-3-yl]methyl]- (9CI) (CA INDEX NAME)



RN 890788-02-0 CAPLUS
CN Benzamide,
N-(2-aminophenyl)-4-[[6-fluoro-2,3-dihydro-3-(2-hydroxypropyl)-2-oxo-1H-benzimidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 890788-10-0 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[[3-(2,3-dihydroxypropyl)-6-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 890788-18-8 CAPLUS

CN Benzamide, N-(4-amino-5-pyrimidinyl)-4-[(6-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890789-14-7 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[1-(2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 890789-30-7 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[1-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 890789-70-5 CAPLUS
CN Benzamide,
N-(4-amino[1,1'-biphenyl]-3-yl)-4-[(6-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890789-78-3 CAPLUS
CN Benzamide, 4-[[5-(acetylamino)-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]methyl]-N-(2-aminophenyl)- (9CI) (CA INDEX NAME)

CN Benzamide, N-(2-aminophenyl)-4-[[2,3-dihydro-2-oxo-3-(4-piperidinyl)-1H-benzimidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 890788-26-8 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[[2,3-dihydro-2-oxo-3-(4-piperidinyl)-1H-imidazo[4,5-b]pyridin-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 890788-34-8 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[[2,3-dihydro-2-oxo-3-(3-piperidinyl)-1H-benzimidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 890788-42-8 CAPLUS
CN Benzamide, N-(4-amino-3-pyridinyl)-4-[(6-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890788-50-8 CAPLUS



RN 890789-86-3 CAPLUS
CN Carbamic acid, [1-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-2,3-dihydro-2-oxo-1H-benzimidazol-5-yl]-, 2-(4-morpholinyl)ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 890789-94-3 CAPLUS
CN Carbamic acid, [1-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-2,3-dihydro-2-oxo-1H-benzimidazol-5-yl]-, 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 890790-02-0 CAPLUS
CN Carbamic acid, [1-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-2,3-dihydro-2-oxo-1H-benzimidazol-5-yl]-, 3-pyridinylmethyl ester (9CI) (CA INDEX NAME)



RN 890790-10-0 CAPLUS

CN 3-Pyridinecarboxamide,
N-[1-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]met
hyl]-2,3-dihydro-2-oxo-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)



RN 890790-18-8 CAPLUS
CN 4-Pyridinecarboxamide,
N-[1-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]met
hyl]-2,3-dihydro-2-oxo-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)



RN 890790-26-8 CAPLUS
CN 2-Pyridinecarboxamide,
N-[1-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]met
hyl]-2,3-dihydro-2-oxo-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)



RN 890790-34-8 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[[5-[[(dimethylamino)acetyl]amino]-2,3-
dihydro-2-oxo-1H-benzimidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 890790-42-8 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(2,3-dihydro-2-oxo-1H-thieno[3,4-
d]imidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890790-50-8 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(2,3-dihydro-2-oxo-1H-imidazo[4,5-
b]pyridin-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890790-72-4 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(2,3-dihydro-2-oxo-1H-imidazo[4,5-
c]pyridin-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890790-93-9 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(1,2-dihydro-2-oxo-3H-imidazo[4,5-
c]pyridin-3-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890791-00-1 CAPLUS
CN Benzamide,
N-(2-aminophenyl)-4-[(6-bromo-1,2-dihydro-2-oxo-3H-imidazo[4,5-
b]pyridin-3-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890791-07-8 CAPLUS
CN Benzamide,
N-(2-aminophenyl)-4-[(1,2-dihydro-1-methyl-2-oxo-3H-imidazo[4,5-

b]pyridin-3-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890791-14-7 CAPLUS
CN Benzamide,
N-(2-aminophenyl)-4-[(1,2-dihydro-2-oxo-1-propyl-3H-imidazo[4,5-
b]pyridin-3-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890791-21-6 CAPLUS
CN Benzamide,
N-(2-aminophenyl)-4-[(1-ethyl-1,2-dihydro-2-oxo-3H-imidazo[4,5-
b]pyridin-3-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890791-28-3 CAPLUS
CN Benzamide,
N-(2-aminophenyl)-4-[(6-chloro-1,2-dihydro-2-oxo-3H-imidazo[4,5-
b]pyridin-3-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890791-35-2 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[[1-(cyclopropylmethyl)-1,2-dihydro-2-oxo-
3H-imidazo[4,5-b]pyridin-3-yl]methyl]- (9CI) (CA INDEX NAME)



RN 890791-42-1 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[[1,2-dihydro-1-(1-methylethyl)-2-oxo-3H-
imidazo[4,5-b]pyridin-3-yl]methyl]- (9CI) (CA INDEX NAME)



RN 890791-82-9 CAPLUS
CN Benzamide, 4-[(1-acetyl-1,2-dihydro-2-oxo-3H-imidazo[4,5-b]pyridin-3-
yl)methyl]-N-(2-aminophenyl)- (9CI) (CA INDEX NAME)



RN 890791-98-7 CAPLUS
CN Benzamide,
N-(2-aminophenyl)-4-[(5-chloro-1,2-dihydro-2-oxo-3H-imidazo[4,5-
b]pyridin-3-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890792-14-0 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(1,2-dihydro-5-methoxy-2-oxo-3H-
imidazo[4,5-b]pyridin-3-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890792-30-0 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[[1-(cyclopropylcarbonyl)-1,2-dihydro-2-oxo-3H-imidazo[4,5-b]pyridin-3-yl]methyl]- (9CI) (CA INDEX NAME)



RN 890792-38-8 CAPLUS
CN Benzamide, 4-[(1,2-dihydro-2-oxo-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-N-[2-[[(dimethylamino)acetyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 890792-46-8 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[[1,2-dihydro-2-oxo-1-(1-oxopropyl)-3H-imidazo[4,5-b]pyridin-3-yl]methyl]- (9CI) (CA INDEX NAME)



IT 890792-54-8 890792-62-8 890792-70-8
890792-78-6 890792-86-6 890792-94-6
890793-02-9 890793-10-9 890793-18-7
890793-26-7 890793-34-7 890793-42-7

890793-50-7 890793-58-5 890793-66-5
890793-74-5 890793-82-5 890793-90-5
890793-98-3 890794-06-6 890794-14-6
890794-22-6 890794-30-6 890794-38-4
890794-46-4 890794-54-4 890794-62-4
890794-70-4 890794-78-2 890794-86-2
890794-94-2 890795-02-5 890795-10-5
890795-18-3 890795-26-3 890795-34-3
890795-42-3 890795-50-3 890795-58-1
890795-66-1 890795-74-1 890795-82-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histone deacetylase inhibitors for use as antitumor, antiarthritic, and anti-Alzheimer drugs)

RN 890792-54-8 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(4-fluoro-2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890792-62-8 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(5-fluoro-2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890792-70-8 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(6-fluoro-2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890792-78-6 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(7-fluoro-2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890792-86-6 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(2,3-dihydro-3-methyl-2-oxo-4-(trifluoromethyl)-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890792-94-6 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(2,3-dihydro-3-methyl-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890793-02-9 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(2,3-dihydro-3-methyl-2-oxo-6-(trifluoromethyl)-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890793-10-9 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(2,3-dihydro-3-methyl-2-oxo-7-(trifluoromethyl)-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890793-18-7 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(2,3-dihydro-4-methoxy-3-methyl-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890793-26-7 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(2,3-dihydro-5-methoxy-3-methyl-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890793-34-7 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(2,3-dihydro-6-methoxy-3-methyl-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890793-42-7 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(2,3-dihydro-7-methoxy-3-methyl-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890793-50-7 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(4-cyano-2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890793-58-5 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(5-cyano-2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890793-66-5 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(7-cyano-2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890793-74-5 CAPLUS
CN 1H-Benzimidazole-5-carboxamide,
1-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-2,3-dihydro-N,3-dimethyl-2-oxo- (9CI) (CA INDEX NAME)



RN 890793-82-5 CAPLUS
CN 1H-Benzimidazole-5-carboxamide,
3-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-2,3-dihydro-N,1-dimethyl-2-oxo- (9CI) (CA INDEX NAME)



RN 890793-90-5 CAPLUS
CN 1H-Benzimidazole-4-carboxamide,
3-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-2,3-dihydro-N,1-dimethyl-2-oxo- (9CI) (CA INDEX NAME)



RN 890793-98-3 CAPLUS
CN 1H-Benzimidazole-4-carboxamide,
1-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-2,3-dihydro-3-methyl-2-oxo-N-(3R)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 890794-06-6 CAPLUS
CN 1H-Benzimidazole-5-carboxamide,
1-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-2,3-dihydro-3-methyl-2-oxo-N-(3R)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 890794-14-6 CAPLUS
CN 1H-Benzimidazole-5-carboxamide,
3-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-2,3-dihydro-1-methyl-2-oxo-N-(3R)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 890794-22-6 CAPLUS
CN 1H-Benzimidazole-4-carboxamide,
3-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-2,3-dihydro-1-methyl-2-oxo-N-(3R)-3-piperidinyl- (9CI) (CA

INDEX NAME)

Absolute stereochemistry.



RN 890794-30-6 CAPLUS
CN 1H-Benzimidazole-4-carboxamide, 1-[[4-[[(2-amino-4-fluorophenyl)amino]carbonyl]phenyl]methyl]-2,3-dihydro-N,3-dimethyl-2-oxo- (9CI) (CA INDEX NAME)



RN 890794-38-4 CAPLUS
CN Benzamide,
N-(2-aminophenyl)-4-[[2,3-dihydro-2-oxo-3-(3R)-3-piperidinyl-1H-benzimidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 890794-46-4 CAPLUS
CN Benzamide,
N-(2-amino-4-fluorophenyl)-4-[(4-fluoro-2,3-dihydro-3-methyl-2-

oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890794-54-4 CAPLUS
CN Benzamide, N-(2-amino-4-fluorophenyl)-4-[[2,3-dihydro-3-methyl-2-oxo-4-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 890794-62-4 CAPLUS
CN Benzamide,
N-(2-amino-4-fluorophenyl)-4-[(2,3-dihydro-4-methoxy-3-methyl-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890794-70-4 CAPLUS
CN Benzamide, N-(2-amino-4-fluorophenyl)-4-[(4-cyano-2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890794-78-2 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)methyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 890794-86-2 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 890794-94-2 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)methyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 890795-02-5 CAPLUS
CN Benzamide, N-(2-aminophenyl)-3-chloro-4-[(2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890795-10-5 CAPLUS
CN Benzamide, N-(2-aminophenyl)-3-bromo-4-[(2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890795-18-3 CAPLUS
CN Benzamide, 3-(acetylamino)-N-(2-aminophenyl)-4-[(2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890795-26-3 CAPLUS
CN Benzamide, N-(2-aminophenyl)-3-(benzoylamino)-4-[(2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890795-34-3 CAPLUS
CN 2-Thiophenecarboxamide, N-[5-[[(2-aminophenyl)amino]carbonyl]-2-[(2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 890795-42-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[5-[[(2-aminophenyl)amino]carbonyl]-2-[(2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 890795-50-3 CAPLUS
CN Benzamide, N-(2-amino-4-fluorophenyl)-4-[(2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)methyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 890795-58-1 CAPLUS
CN Benzamide, N-(2-amino-4-fluorophenyl)-4-[(2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 890795-66-1 CAPLUS
CN Benzamide, N-(2-amino-4-fluorophenyl)-4-[(2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)methyl]-3-fluoro- (9CI) (CA INDEX NAME)

L15 ANSWER 7 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 890795-74-1 CAPLUS
CN Benzamide,
N-(2-amino-4-fluorophenyl)-3-chloro-4-[(2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 890795-82-1 CAPLUS
CN Benzamide, N-(2-amino-4-fluorophenyl)-3-bromo-4-[(2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



L15 ANSWER 8 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
activity in vivo as respiratory syncytial virus fusion inhibitors)

RN 406940-62-3 CAPLUS
CN L-Aspartic acid,
N-[4-[[2,3-dihydro-3-[[1-(3-methylbutyl)-1H-benzimidazol-2-yl]methyl]-2-oxo-1H-benzimidazol-1-yl]methyl]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 406944-05-6 CAPLUS
CN Glycine, N-(carboxymethyl)-N-[4-[[2,3-dihydro-3-[[1-(4-hydroxybutyl)-1H-benzimidazol-2-yl]methyl]-2-oxo-1H-benzimidazol-1-yl]methyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 880550-40-3 CAPLUS
CN L-Alanine, N-[4-[[2,3-dihydro-3-[[1-(3-methylbutyl)-1H-benzimidazol-2-yl]methyl]-2-oxo-1H-benzimidazol-1-yl]methyl]benzoyl]-3-phosphono- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L15 ANSWER 8 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:87873 CAPLUS
DOCUMENT NUMBER: 144:331341
TITLE: Respiratory syncytial virus fusion inhibitors. Part 3:
Water-soluble benzimidazol-2-one derivatives with antiviral activity in vivo
AUTHOR(S): Yu, Kuo-Long; Wang, Xiangdong Alan; Civiello, Rita L.;
Trehan, Ashok K.; Pearce, Bradley C.; Yin, Zhiwei; Combrink, Keith D.; Gulgeze, H. Belgin; Zhang, Yi; Kadow, Kathleen F.; Cianci, Christopher W.; Clarke, Junius; Genovesi, Eugene V.; Medina, Ivette; Lamb, Lucinda; Wyde, Philip R.; Krystal, Mark; Meanwell, Nicholas A.
CORPORATE SOURCE: Department of Chemistry, The Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT, 06492, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(5), 1115-1122
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 144:331341
GI



I

AB The introduction of acidic and basic functionality into the side chains of respiratory syncytial virus (RSV) fusion inhibitors was examined in an effort to identify compds. suitable for evaluation in vivo in the cotton rat model of RSV infection following administration as a small particle aerosol. The acidic compds., e.g. I [R1 = Me2CHCH2CH2; R2 = 4-(HO)2POC6H4CH2, 2-HO3SC6H4CH2], demonstrated potent antiviral activity in cell culture and exhibited efficacy in the cotton rat comparable to ribavirin. In a BALB/c mouse model, the oxadiazolone I [R1 = 2-(5-oxo-1,2,4-oxadiazol-3-yl)ethyl; R2 = Me2CH] reduced virus titers following s.c. dosing, while the ester I (R1 = Me2NCH2CH2; R2 = 4-MeO2CC6H4CH2) and amide I (R1 = Me2NCH2CH2; R2 = 4-Me2NCOC6H4CH2) exhibited efficacy following oral administration. These results established the potential of this class of RSV fusion inhibitors to interfere with infection in vivo following topical or systemic administration.

IT 406940-62-3P 406944-05-6P 880550-40-3P
880550-49-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(water-soluble 1-(benzimidazolylmethyl)-2-benzimidazolones with antiviral

L15 ANSWER 8 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 880550-49-2 CAPLUS
CN Benzamide,
4-[[3-[[1-[2-(dimethylamino)ethyl]-1H-benzimidazol-2-yl]methyl]-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]methyl]-N,N-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 9 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1346218 CAPLUS
DOCUMENT NUMBER: 144:88321
TITLE: Preparation of triazinyl and other carboxamides as inhibitors of histone deacetylase
INVENTOR(S): Delorme, Daniel; Woo, Soon Hyung; Vaisburg, Arkadii; Moradei, Oscar; Leit, Silvana; Raeppel, Stephane; Frechette, Sylvie; Bouchain, Giliane
PATENT ASSIGNEE(S): Methylgene, Inc., Can.
SOURCE: U.S. Pat. Appl. Publ., 324 pp., Cont.-in-part of U.S. Ser. No. 358,556.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2005288282	A1	20051229	US 2005-91025		20050325
US 2004106599	A1	20040603	US 2002-242304		20020912
US 2004142953	A1	20040722	US 2003-358556		20030204
US 6897220	B2	20050524			
JP 2005255683	A	20050922	JP 2005-80310		20050318
AU 2006252047	A1	20070111	AU 2006-252047		20061214
PRIORITY APPLN. INFO.:			US 2001-322402P	P	20010914
			US 2002-391728P	P	20020626
			US 2002-242304	A2	20020912
			US 2003-358556	A2	20030204
			AU 2002-327627	A3	20020912
			JP 2003-528544	A3	20020912

OTHER SOURCE(S): MARPAT 144:88321
GI



I



II

L15 ANSWER 9 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

AB The invention provides compds. and methods for inhibiting histone deacetylase enzymic activity. Such compds. include carboxamides I [Cy2 = (un)substituted cycloalkyl, aryl, heteroaryl, heterocyclyl (each of which is optionally fused to one or two aryl or heteroaryl rings, or to one or two (un)saturated cycloalkyl or heterocyclic rings); X1 = a bond, M1L2M1, L2M2L2 (wherein L2 = a bond, alkylene, alkenylene, alkynylene; M1 = O, S, SO, NHCO, etc.; M2 = M1, heteroarylene, heterocyclylene); Ar2 = (un)substituted (hetero)arylene; R5, R6 = H, alkyl, aryl, aralkyl; q = 0-1; Ay2 = (un)substituted 5-6 membered cycloalkkyl, heterocyclyl or heteroaryl substituted with an amino or hydroxy moiety; with provisos] which were prepared and claimed. E.g., a multi-step synthesis of II, starting from Me 4-(aminomethyl)benzoate.HCl, was given. The invention also provides compns. and methods for treating cell proliferative diseases and conditions. Antineoplastic effects of some I are illustrated for colorectal, pulmonary and pancreatic neoplasms; also the combined antineoplastic effect of histone deacetylase inhibitors and histone deacetylase antisense oligonucleotides on tumor cells in vivo was demonstrated. Although the methods of preparation are not claimed, hundreds of example prepns. are included.

IT 503039-56-3P 503039-58-5P 503042-62-4P
503042-90-8P 503042-91-9P 503042-94-2P
503042-95-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of triazinyl and other carboxamides as inhibitors of histone deacetylase for treating cell proliferative disorders)

RN 503039-56-3 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl)methyl]- (9CI) (CA INDEX NAME)



RN 503039-58-5 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(1,4-dihydro-1-methyl-2,4-dioxo-3(2H)-quinazolinyl)methyl]- (9CI) (CA INDEX NAME)



L15 ANSWER 9 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 503042-62-4 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(1-ethyl-1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl)methyl]- (9CI) (CA INDEX NAME)



RN 503042-90-8 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[[1-[2-(dimethylamino)ethyl]-1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)



RN 503042-91-9 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(1,4-dihydro-1-[2-(4-morpholinyl)ethyl]-2,4-dioxo-3(2H)-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)



RN 503042-94-2 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(6-bromo-1-ethyl-1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl)methyl]- (9CI) (CA INDEX NAME)

L15 ANSWER 9 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 503042-95-3 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(1,4-dihydro-1-[(4-methoxyphenyl)methyl]-2,4-dioxo-3(2H)-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)



L15 ANSWER 10 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1301833 CAPLUS
DOCUMENT NUMBER: 144:63904
TITLE: QSAR studies of N1-(5-chloro-2-pyridyl)-2-{[4-(alkyl methyl)benzoyl]amino}-5-chlorobenzamide analogs
AUTHOR(S): Rameshwar, N.; Krishna, K.; Kumar, B. Ashok; Parthasarathy, T.
CORPORATE SOURCE: Department of Chemistry, Nizam College, Osmania University, Hyderabad, Andhra Pradesh, 500 001, India
SOURCE: Bioorganic & Medicinal Chemistry (2006), 14(2), 319-325
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Factor Xa has materialized as a key enzyme for the intervention of blood coagulation cascade and for the development of new antithrombotic agents. It is the enzyme responsible for the production of thrombin and is therefore an attractive target for the control of thrombus formation. The biol. activities (log 1/IC50) of anthranilamide-based factor Xa inhibitors were quant. analyzed in terms of physicochem. parameters by the regression anal. Structural requirements for maximal potency were derived from the results of a quant. structure activity relationship anal. The leave-one-out cross-validation method was used to judge the predictive power of final equations.

IT 679427-00-0
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(QSAR studies of chlorobenzamide derivs., factor Xa inhibitors)

RN 679427-00-0 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[4-[(2-oxo-1-imidazolidinyl)methyl]benzoyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS

L15 ANSWER 10 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> s l15 not pd>20021204
       5704281 PD>20021204
                     (PD>20021204)
L16           10 L15 NOT PD>20021204

=> d l16 1-10 ibib abs hitstr
```

L16 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:213401 CAPLUS
Correction of: 1997:513626
DOCUMENT NUMBER: 130:209597
Correction of: 127:205470
TITLE: Preparation of heterocyclylhydroxyalkanamides and related compounds as HIV protease inhibitors.
INVENTOR(S): Tung, Roger Dennis; Salituro, Francesco Gerald; Deininger, David D.; Bhisetti, Govinda Rao; Baker, Christopher Todd; Spaltenstein, Andrew; Kazmierski, Wieslaw M.; Andrews, Clarence Webster III
PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
SOURCE: PCT Int. Appl., 336 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9727180	A1	19970731	WO 1997-US1610	19970122
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5883252	A	19990316	US 1996-592777	19960126
US 5945413	A	19990831	US 1996-724563	19960930
AU 9717580	A	19970820	AU 1997-17580	19970122
AU 709239	B2	19990826		
EP 882022	A1	19981209	EP 1997-904911	19970122
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9707086	A	19990413	BR 1997-7086	19970122
JP 2000501111	T	20000202	JP 1997-527124	19970122
NO 9803435	A	19980921	NO 1998-3435	19980724

PRIORITY APPLN. INFO.:			
	US 1996-592777	A	19960126
	US 1996-724563	A2	19960930
	WO 1997-US1610	W	19970122

OTHER SOURCE(S): MARPAT 130:209597
GI

L16 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



II

AB Title compds. [I; Z = (QR1)R1R4, Q1, etc.; ; X, X1 = CO, CO2, SO, SO2; Y, Y1 = [C(R2)2]p, NR2, C:C(R2)2, NR2CH2, etc.; Q = CH, N; R1, R2 = H, (substituted) alkyl, alkenyl, alkynyl, (fused) cycloalkyl, cycloalkenyl, etc.; R4 = (substituted) OR9, XR9, N(R9)2, R6, alkyl, alkenyl, (fused) cycloalkyl, cycloalkenyl, etc.; R5 = H, OH, O, R1; R6 = (substituted) aryl, carbocyclyl, heterocyclyl; R7 = H, OH, O; R9 = H, alkyl, alkenyl, alkynyl, aryl, carbocyclyl, heterocyclyl, aralkyl, carbocyclylalkyl, heterocyclylalkyl; n = 1, 2; r = 0-2}, were prepared Thus, title compound
(II) (preparation given) inhibited HIV protease with Ki = 1.5 nM.
IT 194599-61-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclylhydroxyalkanamides and related compds. as HIV
protease inhibitors)
RN 194599-61-6 CAPLUS
CN D-erythro-Pentonamide, 5-[(5S)-3-[[4-(aminocarbonyl)phenyl]methyl]-2-oxo-5-(phenylmethyl)-1-imidazolidinyl]-2,3,5-trideoxy-N-[(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L16 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:96222 CAPLUS
DOCUMENT NUMBER: 130:168370
TITLE: Preparation of hydantoin derivatives as farnesyl transferase inhibitors
INVENTOR(S): Lee, Jin Ho; Koh, Jong Sung; Kim, Jong Hyun; Lee, Hyun
Il; Jung, Won Hee; Ro, Seong Gu; Shin, You Seung; Kim,
Sang Woong; Park, Ki Won; Kwak, Tae Hwan; Moon, Kyung Duk; Chung, Hyun Ho
PATENT ASSIGNEE(S): LG Chemical Ltd., S. Korea
SOURCE: PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9905117	A1	19990204	WO 1998-KR225	19980724
W: AU, BR, CN, JP, MX, RU, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
ZA 9806623	A	19990126	ZA 1998-6623	19980724
AU 9884647	A	19990216	AU 1998-84647	19980724
AU 729341	B2	20010201		
EP 1000036	A1	20000517	EP 1998-935376	19980724
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001510829	T	20010807	JP 2000-504116	19980724
US 6384061	B1	20020507	US 2000-463551	20000330

PRIORITY APPLN. INFO.:			
	KR 1997-35333	A	19970726
	WO 1998-KR225	W	19980724

OTHER SOURCE(S): MARPAT 130:168370
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R1, R2 = H, lower alkyl, (un)substituted monocyclic or bicyclic aryl; heterocyclyl containing N or S as ring members, etc.; R3 =
amino acid residue, II-V (wherein A = H, lower alkyl, (un)substituted aryl, etc.; B, C = H, halo, lower alkyl; n = 0-4); R4 = H, (un)substituted
aryl, bicyclic aryl, etc.], which showed an inhibitory activity against farnesyl transferase, and thus can be used as an anti-cancer agents, were prepared E.g., a 4-step synthesis of compound VI which showed IC50 of 500 nM
against Ftase and IC50 of > 10 μM against GGtase, was given.
IT 220363-51-9P 220363-52-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L16 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(prepn. of hydantoin derivs. as farnesyl transferase inhibitors)
RN 220363-51-9 CAPLUS
CN Benzamide,
4-[[3-[3-(1H-imidazol-1-yl)propyl]-5-methyl-5-(1-naphthalenyl)-
2,4-dioxo-1-imidazolidinyl]methyl]-N-(2-methoxyethyl)- (9CI) (CA INDEX
NAME)



RN 220363-52-0 CAPLUS
CN Benzamide,
4-[[3-[3-(1H-imidazol-1-yl)propyl]-5-methyl-5-(1-naphthalenyl)-
2,4-dioxo-1-imidazolidinyl]methyl]-N-(2-methoxyethyl)-N-methyl- (9CI)
(CA
INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L16 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:116093 CAPLUS
DOCUMENT NUMBER: 128:128017
TITLE: Preparation of 1-[2-(1-piperidinyl)-1-ethyl]-1,3-dihydro-2H-benzimidazoles for treating central nervous
system disorders
INVENTOR(S): Gallagher, Peter Thaddeus; Miles, Martin Victor; Owton, William Martin; Smith, Colin William
PATENT ASSIGNEE(S): Eli Lilly and Co., Ltd., UK
SOURCE: Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 816356	A1	19980107	EP 1997-304485	19970625
EP 816356	B1	20001102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CA 2208652	A1	19971226	CA 1997-2208652	19970623
US 6075039	A	20000613	US 1997-880450	19970624
JP 10059962	A	19980303	JP 1997-168670	19970625
AT 197299	T	20001115	AT 1997-304485	19970625
ES 2151706	T3	20010101	ES 1997-304485	19970625
PT 816356	T	20010430	PT 1997-304485	19970625
GR 3035251	T3	20010430	GR 2001-400071	20010117
PRIORITY APPLN. INFO.:			GB 1996-13423 A	19960626

OTHER SOURCE(S): MARPAT 128:128017
GI

L16 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I



II

AB The title compds. (I; X = CRaRb, C(O) (wherein Ra, Rb = H, C1-6 alkyl, (un)substituted Ph); Y = O, S; R1, R2, R7 = halo, C1-4 alkyl, C1-4 alkoxy,
etc.; R3-R6 = H, C1-6 alkyl, (un)substituted Ph; n, m, p = 0-3] and their salts, useful for treating central nervous system disorders, were prepared
and formulated. Thus, treatment of 1-[2-[4-(4-fluorobenzoyl)-1-piperidinyl]-1-ethyl]-1,3-dihydro-2H-benzimidazol-2-one with NaH in DMF followed by addition of benzyl bromide afforded the title compound II.HCl.
Compds. I described herein showed Ki of 1-200 nM against serotonin 5-HT1D receptor binding.
IT 201986-13-2P 201986-14-3P 201986-15-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of
1-[2-(1-piperidinyl)-1-ethyl]-1,3-dihydro-2H-benzimidazoles
for treating central nervous system disorders)
RN 201986-13-2 CAPLUS
CN Benzamide,
4-[[3-[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]methyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

L16 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HCl

RN 201986-14-3 CAPLUS
CN Benzamide,
4-[[3-[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]methyl]-N-methyl-, monohydrochloride (9CI) (CA
INDEX NAME)



● HCl

RN 201986-15-4 CAPLUS
CN Benzamide,
4-[[3-[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L16 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HCl

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(substituted) alkyl, alkenyl, alkynyl, (fused) cycloalkyl, cycloalkenyl, etc.; R4 = (substituted) OR9, XR9, N(R9)2, R6, alkyl, alkenyl, (fused) cycloalkyl, cycloalkenyl, etc.; R5 = H, OH, O, R1; R6 = (substituted) aryl, carbocyclyl, heterocyclyl; R7 = H, OH, O; R9 = H, alkyl, alkenyl, alkynyl, aryl, carbocyclyl, heterocyclyl, aralkyl, carbocyclylalkyl, heterocyclylalkyl; n = 1, 2; r = 0-2], were prepd. Thus, title compd. (II) (prepn. given) inhibited HIV protease with Ki = 1.5 nM.

IT 194599-61-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclylhydroxyalkanamides and related compds. as HIV
protease inhibitors)

RN 194599-61-6 CAPLUS

CN D-erythro-Pentonamide, 5-[(5S)-3-[[4-(aminocarbonyl)phenyl]methyl]-2-oxo-5-(phenylmethyl)-1-imidazolidinyl]-2,3,5-trideoxy-N-[(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:513626 CAPLUS
DOCUMENT NUMBER: 127:205470
TITLE: Preparation of heterocyclylhydroxyalkanamides and related compounds as HIV protease inhibitors.
INVENTOR(S): Tung, Roger Dennis; Salituro, Francesco Gerald; Deininger, David D.; Bhisetti, Govinda Rao; Baker, Christopher Todd; Spaltenstein, Andrew; et al.
PATENT ASSIGNEE(S): Vertex Pharmaceuticals Inc., USA; Tung, Roger Dennis; Salituro, Francesco Gerald; Deininger, David D.; Bhisetti, Govinda Rao
SOURCE: PCT Int. Appl., 336 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9727180 A1		19970731	WO 1997-US1610	19970122
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 1996-592777	19960126
			US 1996-724563	19960930

OTHER SOURCE(S): MARPAT 127:205470
GI



I



II

AB Title compds. [I; Z = (QR1)rX1R4, Q1, etc.; ; X, X1 = CO, CO2, SO, SO2; Y,
Y1 = (C(R2)2]p, NR2, C:C(R2)2, NR2CH2, etc.; Q = CH, N; R1, R2 = H,

L16 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:310799 CAPLUS
DOCUMENT NUMBER: 126:293363
TITLE: Preparation of 2-phenylsulfonyl- and 2-(heterocyclylsulfonyl)quinazoline derivatives as chymase inhibitors
INVENTOR(S): Fukami, Harukazu; Ito, Akiko; Niwata, Shinjiro; Kakutani, Saki; Sumida, Motoo; Kiso, Yoshinobu
PATENT ASSIGNEE(S): Suntory Limited, Japan
SOURCE: PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9711941	A1	19970403	WO 1996-JP2830	19960927
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 795548	A1	19970917	EP 1996-932039	19960927
EP 795548	B1	20020703		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
ES 2175127	T3	20021116	ES 1996-932039	19960927
US 5814631	A	19980929	US 1997-849114	19970528
PRIORITY APPLN. INFO.:			JP 1995-285437 A	19950928
			JP 1996-116557 A	19960510
			WO 1996-JP2830 W	19960927

OTHER SOURCE(S): MARPAT 126:293363
GI



I

AB Quinazoline derivs. represented by general formula [I; group A = benzene, pyridine, pyrrole, or pyrazole ring; m = 0-2; X = OH, NO2, halo, C1-4 (halo)alkyl, or (halo)alkoxy, C7-12 aralkyloxy; X = group to form a naphthalene or quinoline ring together with the benzene ring to which X is
attached; R1, R2 = H, halo, C1-4 (halo)alkyl, NO2, cyano, pyrazolyl, tetrazolyl, C1-4 alkyl, CO2H, allyloxycarbonyl, C1-4 (un)substituted alkoxy; or R1 and R2 together with the benzene ring represent a naphthalene or quinoline ring; Z = H, C1-4 (halo)alkyl, C2-5 alkenyl, (un)substituted aralkyl, aromatic heterocyclylalkyl, C1-4 alkoxycarbonylmethyl, allyloxycarbonylmethyl, (1° or 2° amino)carbonylmethyl, (un)substituted aralkyloxymethyl; proviso given] or

L16 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
pharmacol. acceptable salts thereof are prepd. They are useful as preventives/remedies for cardiac and circulatory diseases (e.g. hypertension or heart failure) caused by abnormal overprodn. of angiotensin II. Thus, a quinazolinedione deriv. (II; R = H) (prepn. given) was condensed with 3-(diethylamino)-1,5-dihydro-2,4,3-benzodioxaphosphepine in the presence of tetrazole in DMF, followed by oxidn. with m-chloroperbenzoic acid in CH2Cl2 and hydrogenolysis over 10% Pd-C in dioxane under H atm. to give II (R = P(O)(OH)2). II (R = H) and II (R = P(O)(OH)2) showed IC50 of 0.060 and 0.025 μM, resp., for inhibiting human heart chymase. The title compds. I also inhibited cathepsin G and chymotrypsin. Formulation examples contg. I were given.

IT 189061-89-0P 189061-91-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-phenylsulfonyl- and N-(heterocyclylsulfonyl)quinazoline derivs. as chymase inhibitors for treating heart or circulatory diseases)

RN 189061-89-0 CAPLUS
CN Benzamide, 4-[[7-chloro-3-[(4-chlorophenyl)sulfonyl]-3,4-dihydro-2,4-dioxo-1(2H)-quinazolinyl]methyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 189061-91-4 CAPLUS
CN Glycine, N-[4-[[7-chloro-3-[(4-chlorophenyl)sulfonyl]-3,4-dihydro-2,4-dioxo-1(2H)-quinazolinyl]methyl]benzoyl]- (9CI) (CA INDEX NAME)

L16 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 189062-87-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-phenylsulfonyl- and N-(heterocyclylsulfonyl)quinazoline derivs. as chymase inhibitors for treating heart or circulatory diseases)

RN 189062-87-1 CAPLUS
CN Glycine, N-[4-[[3-[(4-chlorophenyl)sulfonyl]-3,4-dihydro-2,4-dioxo-1(2H)-quinazolinyl]methyl]benzoyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L16 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:231458 CAPLUS
DOCUMENT NUMBER: 126:301779
TITLE: Method of treating human immunodeficiency virus infection using a cyclic protease inhibitor in combination with a reverse transcriptase inhibitor
INVENTOR(S): Otto, Michael J.
PATENT ASSIGNEE(S): Dupont Merck Pharmaceutical Co., USA
SOURCE: U.S., 37 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5616578	A	19970401	US 1993-110603	19930826
PRIORITY APPLN. INFO.:			US 1993-110603	19930826

OTHER SOURCE(S): MARPAT 126:301779

AB A method of treating human immunodeficiency virus (HIV) infection in a mammal comprises administering a synergistically and therapeutically effective amount of a combination of: (1) ≥1 cyclic HIV protease inhibitor and (2) ≥1 HIV reverse transcriptase inhibitor. More than 200 cyclic compound protease inhibitors are disclosed. The reverse transcriptase inhibitor may be AZT, ddI, ddC, d4T, or 3TC.

IT 153183-56-3 153183-61-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclic protease inhibitor synergistic combination with reverse transcriptase inhibitor for treatment of HIV infection)

RN 153183-56-3 CAPLUS
CN Benzoic acid, 4,4'-[[tetrahydro-5,6-dihydroxy-2-oxo-4,7-bis(phenylmethyl)-1H-1,3-diazepine-1,3(2H)-diyl]bis(methylene)]bis-, dihydrazide, [4R-(4α,5α,6β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 153183-61-0 CAPLUS
CN Benzamide, 4,4'-[[tetrahydro-5,6-dihydroxy-2-oxo-4,7-bis(phenylmethyl)-1H-1,3-diazepine-1,3(2H)-diyl]bis(methylene)]bis[N-methoxy-, [4R-(4α,5α,6β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:259446 CAPLUS
DOCUMENT NUMBER: 124:289534
TITLE: 1-Benzyl-1,3-dihydro-2H-benzimidazol-2-one derivatives, their preparation, and pharmaceutical compositions containing them as vasopressin and/or oxytocin receptor ligands.
INVENTOR(S): Di Malta, Alain; Mettefeu, Daniel; Garcia, Georges; Roux, Richard; Serradeil-Legal, Claudine
PATENT ASSIGNEE(S): Sanofi, Fr.
SOURCE: Eur. Pat. Appl., 49 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 694536	A1	19960131	EP 1995-401599	19950704
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
FR 2722190	A1	19960112	FR 1994-8278	19940705
FR 2722190	B1	19961004		
JP 08073439	A	19960319	JP 1995-170048	19950705
US 5661169	A	19970826	US 1995-498542	19950705
PRIORITY APPLN. INFO.:			FR 1994-8278 A	19940705

OTHER SOURCE(S): CASREACT 124:289534; MARPAT 124:289534
GI



AB Over 50 examples of title compds. I [R1 = halo, alkyl, alkylthio, PhS, CF3, cyano, NO2, (un)substituted amino, OH, alkoxy, etc.; R2 = H, halo, alkyl; R3 = R4, (CH2)pR4, indanyl, adamantyl, (un)substituted cyclohexyl, etc.; R4 = (un)substituted amino, (un)substituted cycloalkyl, furyl, thienyl, pyrrolyl, pyridyl, etc.; R5 = H, alkyl, alkoxy, halo, OH, CF3; R6 = cyano, (un)substituted amino or aminomethyl, aryl, OH, alkoxy, etc.; p = 1-8] were prepared For example, 2,4-dichloro-1-nitrobenzene underwent a sequence of condensation with cyclohexylamine, reduction of the nitro group,

L16 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 175866-20-3 CAPLUS
CN Benzamide, 4-[(3-cyclohexyl-5-ethoxy-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)methyl]-N-[2-(dimethylamino)-1,1-dimethylethyl]-3-methoxy- (9CI) (CA INDEX NAME)



L16 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
and cyclocondensation with urea, to give 5-chloro-3-cyclohexyl-1,3-dihydro-2H-benzimidazol-2-one. This was N-alkylated with 1-(bromomethyl)-3,4-dimethoxybenzene, using NaH in THF, to give title compd. II. In various receptor binding assays, I had IC50 values down to 10-6 M for V1, 10-9 M for V2, and 10-6 M for oxytocin receptors.
IT 175865-86-8P 175865-87-9P 175865-88-0P 175866-20-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzyldihydrobenzimidazolone derivs. as vasopressin and/or oxytocin receptor ligands)
RN 175865-86-8 CAPLUS
CN Benzamide, 4-[(3-cyclohexyl-5-ethoxy-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)methyl]-N-(1,1-dimethylethyl)-3-methoxy- (9CI) (CA INDEX NAME)



RN 175865-87-9 CAPLUS
CN Benzamide, 4-[(3-cyclohexyl-5-ethoxy-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)methyl]-N-(1,1-dimethylbutyl)-3-methoxy- (9CI) (CA INDEX NAME)



RN 175865-88-0 CAPLUS
CN Benzamide, N-(1,1-dimethylethyl)-4-[[5-ethoxy-2,3-dihydro-2-oxo-3-(tetrahydro-2H-pyran-4-yl)-1H-benzimidazol-1-yl]methyl]-3-methoxy- (9CI) (CA INDEX NAME)

L16 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:746699 CAPLUS
DOCUMENT NUMBER: 123:132007
TITLE: Computer-Aided Design and Synthesis of 5-Substituted Tryptamines and Their Pharmacology at the 5-HT1D Receptor: Discovery of Compounds with Potential Anti-Migraine Properties
AUTHOR(S): Buckingham, Janet; Glen, Robert C.; Hill, Alan P.; Hyde, Richard M.; Martin, Graeme R.; Robertson, Alan D.; Salmon, John A.; Woollard, Patrick M.
CORPORATE SOURCE: Wellcome Research Laboratories, Beckenham/Kent, BR3 3BS, UK
SOURCE: Journal of Medicinal Chemistry (1995), 38(18), 3566-80
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The design and synthesis of a series of novel 5-substituted tryptamines with pharmacol. activity at 5-HT1D and other monoamine receptors is described. Structural modifications of N- and C-linked (principally hydantoin) analogs at the 5-position were synthesized and their pharmacol. activities were utilized to deduce significant steric and electrostatic requirements of the 5-HT1D and 5-HT2A receptor subtypes. Conformations of the active mols. were computed which, when overlaid, suggested a pharmacophore hypothesis which was consistent with the affinity and selectivity measured at 5-HT1D and 5-HT2A receptors. This pharmacophore is composed of a protonated amine site, an aromatic site, a hydrophobic pocket, and two hydrogen-bonding sites. A "selectivity site" was also identified which, if occupied, induced selectivity for 5-HT1D over 5-HT2A in this series of mols. The development and use of the pharmacophore models in compound design is described. In addition, the physicochem. constraints of mol. size and hydrophobicity required for efficient oral absorption are discussed. Utilizing the pharmacophore model in conjunction with the physicochem. constraints of mol. size and log DpH7.4 led to the discovery of 311C90 (6), a new selective 5-HT1D agonist with good oral absorption and potential use in the treatment of migraine.
IT 165605-47-0P
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(design and synthesis and pharmacol. at 5-HT1D receptor of tryptamine derivs.)
RN 165605-47-0 CAPLUS
CN Benzamide, 4-[[4-[[3-(2-aminoethyl)-1H-indol-5-yl]methyl]-2,5-dioxo-1-imidazolidinyl]methyl]-N-phenyl- (9CI) (CA INDEX NAME)

L16 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L16 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1989:632814 CAPLUS
DOCUMENT NUMBER: 111:232814
TITLE: Preparation and formulation of heterocyclic compounds for use as therapeutic agents particularly in treatment of migraine
INVENTOR(S): Robertson, Alan Duncan; Martin, Graeme Richard; Buckingham, Janet Susan
PATENT ASSIGNEE(S): Wellcome Foundation Ltd., UK
SOURCE: Eur. Pat. Appl., 37 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 313397	A1	19890426	EP 1988-309943	19881021
EP 313397	B1	19930602		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DK 8805865	A	19890424	DK 1988-5865	19881021
FI 8804879	A	19890424	FI 1988-4879	19881021
JP 01146882	A	19890608	JP 1988-265917	19881021
JP 2501631	B2	19960529		
CN 1035113	A	19890830	CN 1988-108816	19881021
HU 50163	A2	19891228	HU 1988-5431	19881021
HU 202230	B	19910228		
ZA 8807900	A	19900627	ZA 1988-7900	19881021
DD 283140	A5	19901003	DD 1988-320940	19881021
PL 158305	B1	19920831	PL 1988-275423	19881021
AT 90089	T	19930615	AT 1988-309943	19881021
ES 2054825	T3	19940816	ES 1988-309943	19881021
AU 8824181	A	19890427	AU 1988-24181	19881024
AU 604165	B2	19901206		
US 5225431	A	19930706	US 1991-660966	19910226
PRIORITY APPLN. INFO.:			GB 1987-24912 A	19871023
			EP 1988-309943 A	19881021
			US 1988-260885 B1	19881021

GI



AB Title compds. I (R, R1, R2 = H, C1-4 alkyl; R3, R4 = H, (un)substituted C1-6 alkyl, C1-6 cycloalkyl, (un)substituted C1-6 aryl, (un)substituted PhCH2, provided R3 = (un)substituted PhCH2 where R4 = H; W = heterocycly; X = (un)substituted aryl, heteroaryl, xanthenyl, or dibenzofuranyl; m = 0-2; n = 0-3) salts and solvates thereof, are prepared

L16 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

(-)-4'-[2-[4-(4-Nitrobenzyl)-2,5-dioxoimidazolidinyl]ethyl]acetanilide (prepn. given) was added to HCHO in MeOH, NaBH3CN and AcOH in MeOH, the mixt. was stirred for 2.5 h, satd. aq. K2CO3 was added to give (-)-I [X(CH2)nW(CH2)m = [2-[5-[1-[2-(4-acetamidophenyl)ethyl]-2,5-dioxoimidazolidin-4-ylmethyl]; R, R1, R2 = H; R3, R4 = Me]. Similarly prepd. was (±)-2-[5-(1-benzyl-3-methyl-2-oxoimidazolidin-4-ylmethyl-1H-indol-3-yl]ethylamine maleate (II). In test for activity as agonist of 5-HT1-like receptor mediating smooth muscle contraction, II was the most active. Numerous formulations contg. I are presented.

IT 123945-55-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for treatment of migraine)

RN 123945-55-1 CAPLUS

CN Benzamide, 4-[[4-[[3-(2-aminoethyl)-1H-indol-5-yl]methyl]-2,5-dioxo-1-imidazolidinyl]methyl]-N-phenyl-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 165605-47-0
CMF C28 H27 N5 O3



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L16 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1973:4279 CAPLUS
DOCUMENT NUMBER: 78:4279
TITLE: Anticonvulsive 1-benzyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinones
INVENTOR(S): Schwan, Thomas James; Honkomp, Leroy Joseph; Castellion, Alan William; Burns, Richard Henry
PATENT ASSIGNEE(S): Morton-Norwich Products, Inc.
SOURCE: Ger. Offen., 20 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2214474	A	19721005	DE 1972-2214474	19720324
IL 39003	A	19750210	IL 1972-39003	19720316
ZA 7201832	A	19731031	ZA 1972-1832	19720317
ES 400964	A1	19750901	ES 1972-400964	19720320
GB 1327552	A	19730822	GB 1972-13248	19720321
DK 129523	B	19741021	DK 1972-1339	19720322
BE 781158	A1	19720925	BE 1972-115497	19720323
NL 7203883	A	19720927	NL 1972-3883	19720323
AT 315184	B	19740510	AT 1972-2541	19720323
CH 568299	A5	19751031	CH 1972-4347	19720323
FR 2130686	A5	19721103	FR 1972-10486	19720324
FR 2130686	B1	19750620		
CA 965416	A1	19750401	CA 1972-138099	19720324
US 3833586	A	19740903	US 1973-330113	19730206
CA 996114	A2	19760831	CA 1974-215150	19741203
PRIORITY APPLN. INFO.:			US 1971-128143 A	19710325
			CA 1972-138099 A3	19720324

GI For diagram(s), see printed CA Issue.

AB Nine title compds. (I, R = H, p-HO2C, p-MeO2C, p-H2NCO, p-Me(CH2)7, m-F3C, p-Me, p-H2NCH2, p-Me2N; R1 = H, Ph), used as anticonvulsants and tranquilizers, were prepared Thus, 2-hydroxypyrimidine-HCl was refluxed with p-BrCH2C6H4CO2Me and K2CO3 in MeOH in the presence of KI to give 34% Me p-[1,2-dihydro-k-oxo-1-pyrimidinyl)methyl]benzoate, which was hydrogenated over PtO2 in MeOH at 8 kg/cm2 to give 100% I (R = p-MeO2C, R1 = H).

IT 40016-22-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 40016-22-6 CAPLUS

CN Benzamide, 4-[(tetrahydro-2-oxo-1(2H)-pyrimidinyl)methyl]- (9CI) (CA INDEX NAME)



=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	121.51	825.74

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-15.60	-17.16

STN INTERNATIONAL LOGOFF AT 17:58:38 ON 06 SEP 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJHM1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	MAY 01	New CAS web site launched
NEWS 3	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS 4	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 5	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS 6	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS 7	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS 8	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents
NEWS 9	JUN 27	CA/CAplus enhanced with pre-1967 CAS Registry Numbers
NEWS 10	JUN 29	STN Viewer now available
NEWS 11	JUN 29	STN Express, Version 8.2, now available
NEWS 12	JUL 02	LEMBASE coverage updated
NEWS 13	JUL 02	LMEDLINE coverage updated
NEWS 14	JUL 02	SCISEARCH enhanced with complete author names
NEWS 15	JUL 02	CHEMCATS accession numbers revised
NEWS 16	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 17	JUL 16	CAplus enhanced with French and German abstracts
NEWS 18	JUL 18	CA/CAplus patent coverage enhanced